Artiva Biotherapeutics, Inc. financial data

Symbol
ARTV on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1190% %
Debt-to-equity 15% %
Return On Equity -60% % 95%
Return On Assets -52% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24,716,672 shares 1.5%
Entity Public Float $15,000,000 USD
Common Stock, Value, Issued $3,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 24,444,057 shares 117%
Weighted Average Number of Shares Outstanding, Diluted 24,444,057 shares 117%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $69,540,000 USD 38%
General and Administrative Expense $20,270,000 USD 18%
Operating Income (Loss) $89,810,000 USD -33%
Nonoperating Income (Expense) $5,945,000 USD 211%
Net Income (Loss) Attributable to Parent $83,865,000 USD -28%
Earnings Per Share, Basic -3.43 USD/shares 41%
Earnings Per Share, Diluted -3.43 USD/shares 41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $26,701,000 USD -34%
Cash, Cash Equivalents, and Short-term Investments $108,000,000 USD -42%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Assets, Current $112,666,000 USD -40%
Property, Plant and Equipment, Net $6,618,000 USD 3.9%
Operating Lease, Right-of-Use Asset $10,525,000 USD -24%
Other Assets, Noncurrent $458,000 USD 72%
Assets $130,940,000 USD -38%
Accounts Payable, Current $355,000 USD -68%
Employee-related Liabilities, Current $7,569,000 USD 57%
Accrued Liabilities, Current $9,600,000 USD 30%
Liabilities, Current $13,087,000 USD 6.8%
Operating Lease, Liability, Noncurrent $7,883,000 USD -25%
Other Liabilities, Noncurrent $73,000 USD 0%
Liabilities $20,970,000 USD -8.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax $103,000 USD
Retained Earnings (Accumulated Deficit) $330,549,000 USD -34%
Stockholders' Equity Attributable to Parent $109,970,000 USD -41%
Liabilities and Equity $130,940,000 USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $19,841,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $239,000 USD
Net Cash Provided by (Used in) Investing Activities $9,971,000 USD 1.9%
Common Stock, Shares Authorized 700,000,000 shares
Common Stock, Shares, Issued 424,000 shares 0%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $9,631,000 USD -82%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27,162,000 USD -33%
Deferred Tax Assets, Valuation Allowance $87,643,000 USD 39%
Deferred Tax Assets, Gross $91,276,000 USD 34%
Operating Lease, Liability $10,898,000 USD -23%
Depreciation $2,500,000 USD 4.2%
Payments to Acquire Property, Plant, and Equipment $511,000 USD 2739%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $83,633,000 USD -27%
Lessee, Operating Lease, Liability, to be Paid $12,527,000 USD -26%
Property, Plant and Equipment, Gross $15,075,000 USD 23%
Operating Lease, Liability, Current $3,015,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,497,000 USD -0.91%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,143,000 USD -23%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 3.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,629,000 USD -43%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,603,000 USD 2.4%
Deferred Tax Assets, Operating Loss Carryforwards $54,930,000 USD 85%
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $6,206,000 USD 24%
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,284,000 USD -37%
Depreciation, Depletion and Amortization $628,000 USD 7%
Deferred Tax Assets, Net of Valuation Allowance $3,633,000 USD -28%
Share-based Payment Arrangement, Expense $6,821,000 USD -2.3%